Viking Therapeutics (NasdaqCM:VKTX) has experienced an 11% monthly decline in its stock price, a notable movement amid its recent announcements and a wider market downturn. The company completed the ...
With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of ...
Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.
J&J said the U.S. expansion plan will represent a 25% increase in its investment compared to the past four years. In its annual reports, the company said it spent around $4 billion each year between ...
An aerial sketch of CordenPharma’s future peptide manufacturing facility in Muttenz, Switzerland. Image: CordenPharma. As part of its growth initiatives, CordenPharma has finalized plans to establish ...
Viking Therapeutics, Inc. (Viking), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that it has signed a broad ...
Yesterday, Viking signed a "broad manufacturing agreement" with Germany's CordenPharma to produce for it a "multi-ton annual ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics ( VKTX 2.08 ...
Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor ...
Viking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and manufacturing organization (CDMO), for both the oral and subcutaneous (SC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback